This study is being conducted to evaluate the effectiveness and safety of a medication called vamifeport in adults with HFE-related hereditary hemochromatosis. This condition is a type of hereditary hemochromatosis, which is a genetic disorder that causes the body to absorb too much iron from food. Over time, this extra iron can build up in organs like the liver, potentially causing damage.

Participants in this study will be randomly assigned to receive either the experimental drug CSL624, which contains vamifeport trihydrochloride in a hard capsule form, or a placebo. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being administered. During the study, the amount of iron in the liver will be monitored using MRI, a type of medical imaging that uses magnets to create detailed pictures of the inside of the body, to measure the liver iron concentration.